PDF(Pubmed)
Abstract：
BACKGROUND: Small cell lung cancer (SCLC) is a common and aggressive subtype of lung cancer. It is characterized by rapid growth and a high mortality rate. Approximately 10% of patients with SCLC present with brain metastases at the time of diagnosis, which is associated with a median survival of 5 mo. This study aimed to summarize the effect of bevacizumab on the progression-free survival (PFS) and overall survival of patients with brain metastasis of SCLC.
METHODS: A 62-year-old man was referred to our hospital in February 2023 because of dizziness and numbness of the right lower extremity without headache or fever for more than four weeks. The patient was diagnosed with limited-stage SCLC. He received 8 cycles of chemotherapy combined with maintenance bevacizumab therapy and achieved a PFS of over 7 mo.
CONCLUSIONS: The combination of bevacizumab and irinotecan effectively alleviated brain metastasis in SCLC and prolonged PFS.
METHODS: A 62-year-old man was referred to our hospital in February 2023 because of dizziness and numbness of the right lower extremity without headache or fever for more than four weeks. The patient was diagnosed with limited-stage SCLC. He received 8 cycles of chemotherapy combined with maintenance bevacizumab therapy and achieved a PFS of over 7 mo.
CONCLUSIONS: The combination of bevacizumab and irinotecan effectively alleviated brain metastasis in SCLC and prolonged PFS.
摘要：
背景：小细胞肺癌（SCLC）是一种常见的侵袭性肺癌亚型。它的特点是快速增长和高死亡率。大约10%的SCLC患者在诊断时出现脑转移，这与5个月的中位生存期有关。本研究旨在总结贝伐单抗对SCLC脑转移患者无进展生存期(PFS)和总生存期的影响。
方法：2023年2月，一名62岁的男子因右下肢头晕麻木而被转诊至我院，治疗时间超过4周，无头痛或发热。患者被诊断为局限期SCLC。他接受了8个周期的化疗联合贝伐单抗维持治疗，PFS超过7个月。
结论：贝伐单抗联合伊立替康可有效缓解SCLC脑转移，延长PFS。
方法：2023年2月，一名62岁的男子因右下肢头晕麻木而被转诊至我院，治疗时间超过4周，无头痛或发热。患者被诊断为局限期SCLC。他接受了8个周期的化疗联合贝伐单抗维持治疗，PFS超过7个月。
结论：贝伐单抗联合伊立替康可有效缓解SCLC脑转移，延长PFS。
